Peringatan Keamanan

Hepatotoxic.

Chenodeoxycholic acid

DB06777

small molecule approved

Deskripsi

Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated.

Struktur Molekul 2D

Berat 392.572
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Chenodiol is well absorbed from the small intestine.

Metabolisme

Chenodiol is well absorbed from the small intestine and taken up by the liver where it is converted to its taurine and glycine conjugates and secreted in bile. At steady-state, an amount of chenodiol near the daily dose escapes to the colon and is converted by bacterial action to lithocholic acid. About 80% of the lithocholate is excreted in the feces; the remainder is absorbed and converted in the liver to its poorly absorbed sulfolithocholyl conjugates. During chenodiol therapy there is only a minor increase in biliary lithocholate, while fecal bile acids are increased three- to fourfold.

Rute Eliminasi

About 80% of its bacterial metabolite lithocholate is excreted in the feces.

Interaksi Obat

325 Data
Lepirudin The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Chenodeoxycholic acid.
Bivalirudin The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Chenodeoxycholic acid.
Alteplase The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Chenodeoxycholic acid.
Urokinase The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Chenodeoxycholic acid.
Reteplase The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Chenodeoxycholic acid.
Anistreplase The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Chenodeoxycholic acid.
Tenecteplase The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Chenodeoxycholic acid.
Drotrecogin alfa The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Chenodeoxycholic acid.
Streptokinase The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Chenodeoxycholic acid.
Dicoumarol The risk or severity of bleeding and bruising can be increased when Dicoumarol is combined with Chenodeoxycholic acid.
Argatroban The risk or severity of bleeding and bruising can be increased when Argatroban is combined with Chenodeoxycholic acid.
Ardeparin The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Chenodeoxycholic acid.
Phenindione The risk or severity of bleeding and bruising can be increased when Phenindione is combined with Chenodeoxycholic acid.
Fondaparinux The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Chenodeoxycholic acid.
Warfarin The risk or severity of bleeding and bruising can be increased when Warfarin is combined with Chenodeoxycholic acid.
Pentosan polysulfate The risk or severity of bleeding and bruising can be increased when Pentosan polysulfate is combined with Chenodeoxycholic acid.
Phenprocoumon The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Chenodeoxycholic acid.
Heparin The risk or severity of bleeding and bruising can be increased when Heparin is combined with Chenodeoxycholic acid.
Enoxaparin The risk or severity of bleeding and bruising can be increased when Enoxaparin is combined with Chenodeoxycholic acid.
Acenocoumarol The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Chenodeoxycholic acid.
4-hydroxycoumarin The risk or severity of bleeding and bruising can be increased when 4-hydroxycoumarin is combined with Chenodeoxycholic acid.
Coumarin The risk or severity of bleeding and bruising can be increased when Coumarin is combined with Chenodeoxycholic acid.
Ximelagatran The risk or severity of bleeding and bruising can be increased when Ximelagatran is combined with Chenodeoxycholic acid.
Desmoteplase The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Chenodeoxycholic acid.
Ancrod The risk or severity of bleeding and bruising can be increased when Ancrod is combined with Chenodeoxycholic acid.
Rivaroxaban The risk or severity of bleeding and bruising can be increased when Rivaroxaban is combined with Chenodeoxycholic acid.
Sulodexide The risk or severity of bleeding and bruising can be increased when Sulodexide is combined with Chenodeoxycholic acid.
Semuloparin The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Chenodeoxycholic acid.
Idraparinux The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Chenodeoxycholic acid.
Astaxanthin The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Chenodeoxycholic acid.
Apixaban The risk or severity of bleeding and bruising can be increased when Apixaban is combined with Chenodeoxycholic acid.
Otamixaban The risk or severity of bleeding and bruising can be increased when Otamixaban is combined with Chenodeoxycholic acid.
Amediplase The risk or severity of bleeding and bruising can be increased when Amediplase is combined with Chenodeoxycholic acid.
Dabigatran etexilate The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Chenodeoxycholic acid.
Danaparoid The risk or severity of bleeding and bruising can be increased when Danaparoid is combined with Chenodeoxycholic acid.
Dalteparin The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Chenodeoxycholic acid.
Tinzaparin The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Chenodeoxycholic acid.
(R)-warfarin The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Chenodeoxycholic acid.
Ethyl biscoumacetate The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Chenodeoxycholic acid.
Nadroparin The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Chenodeoxycholic acid.
Ditazole The risk or severity of bleeding and bruising can be increased when Ditazole is combined with Chenodeoxycholic acid.
Edoxaban The risk or severity of bleeding and bruising can be increased when Edoxaban is combined with Chenodeoxycholic acid.
Sodium citrate The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Chenodeoxycholic acid.
Dextran The risk or severity of bleeding and bruising can be increased when Dextran is combined with Chenodeoxycholic acid.
Bemiparin The risk or severity of bleeding and bruising can be increased when Bemiparin is combined with Chenodeoxycholic acid.
Parnaparin The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Chenodeoxycholic acid.
Desirudin The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Chenodeoxycholic acid.
Antithrombin Alfa The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Chenodeoxycholic acid.
Protein C The risk or severity of bleeding and bruising can be increased when Protein C is combined with Chenodeoxycholic acid.
Antithrombin III human The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Chenodeoxycholic acid.
Letaxaban The risk or severity of bleeding and bruising can be increased when Letaxaban is combined with Chenodeoxycholic acid.
Darexaban The risk or severity of bleeding and bruising can be increased when Darexaban is combined with Chenodeoxycholic acid.
Betrixaban The risk or severity of bleeding and bruising can be increased when Betrixaban is combined with Chenodeoxycholic acid.
Nafamostat The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Chenodeoxycholic acid.
Monteplase The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Chenodeoxycholic acid.
Gabexate The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Chenodeoxycholic acid.
Fluindione The risk or severity of bleeding and bruising can be increased when Fluindione is combined with Chenodeoxycholic acid.
Protein S human The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Chenodeoxycholic acid.
Brinase The risk or severity of bleeding and bruising can be increased when Brinase is combined with Chenodeoxycholic acid.
Clorindione The risk or severity of bleeding and bruising can be increased when Clorindione is combined with Chenodeoxycholic acid.
Diphenadione The risk or severity of bleeding and bruising can be increased when Diphenadione is combined with Chenodeoxycholic acid.
Tioclomarol The risk or severity of bleeding and bruising can be increased when Tioclomarol is combined with Chenodeoxycholic acid.
Melagatran The risk or severity of bleeding and bruising can be increased when Melagatran is combined with Chenodeoxycholic acid.
Saruplase The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Chenodeoxycholic acid.
(S)-Warfarin The risk or severity of bleeding and bruising can be increased when (S)-Warfarin is combined with Chenodeoxycholic acid.
Tocopherylquinone The risk or severity of bleeding and bruising can be increased when Tocopherylquinone is combined with Chenodeoxycholic acid.
Dabigatran The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Chenodeoxycholic acid.
Troxerutin The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Chenodeoxycholic acid.
Edetic acid The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Chenodeoxycholic acid.
Reviparin The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Chenodeoxycholic acid.
Dermatan sulfate The risk or severity of bleeding and bruising can be increased when Dermatan sulfate is combined with Chenodeoxycholic acid.
SR-123781A The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Chenodeoxycholic acid.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Chenodeoxycholic acid.
Eptifibatide The risk or severity of adverse effects can be increased when Eptifibatide is combined with Chenodeoxycholic acid.
Ticlopidine The risk or severity of adverse effects can be increased when Ticlopidine is combined with Chenodeoxycholic acid.
Anagrelide The risk or severity of adverse effects can be increased when Anagrelide is combined with Chenodeoxycholic acid.
Clopidogrel The risk or severity of adverse effects can be increased when Clopidogrel is combined with Chenodeoxycholic acid.
Tirofiban The risk or severity of adverse effects can be increased when Tirofiban is combined with Chenodeoxycholic acid.
Pentoxifylline The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Chenodeoxycholic acid.
Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Chenodeoxycholic acid.
Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Chenodeoxycholic acid.
Sulfinpyrazone The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Chenodeoxycholic acid.
Cilostazol The risk or severity of adverse effects can be increased when Cilostazol is combined with Chenodeoxycholic acid.
Ridogrel The risk or severity of adverse effects can be increased when Ridogrel is combined with Chenodeoxycholic acid.
Epoprostenol The risk or severity of adverse effects can be increased when Epoprostenol is combined with Chenodeoxycholic acid.
Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Chenodeoxycholic acid.
Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Chenodeoxycholic acid.
Tesmilifene The risk or severity of adverse effects can be increased when Tesmilifene is combined with Chenodeoxycholic acid.
Defibrotide The risk or severity of adverse effects can be increased when Defibrotide is combined with Chenodeoxycholic acid.
Beraprost The risk or severity of adverse effects can be increased when Beraprost is combined with Chenodeoxycholic acid.
Ibudilast The risk or severity of adverse effects can be increased when Ibudilast is combined with Chenodeoxycholic acid.
Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Chenodeoxycholic acid.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Chenodeoxycholic acid.
Prasugrel The risk or severity of adverse effects can be increased when Prasugrel is combined with Chenodeoxycholic acid.
Cangrelor The risk or severity of adverse effects can be increased when Cangrelor is combined with Chenodeoxycholic acid.
Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Chenodeoxycholic acid.
Triflusal The risk or severity of adverse effects can be increased when Triflusal is combined with Chenodeoxycholic acid.
Ticagrelor The risk or severity of adverse effects can be increased when Ticagrelor is combined with Chenodeoxycholic acid.
Icosapent ethyl The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Chenodeoxycholic acid.
Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Chenodeoxycholic acid.

Target Protein

Bile acid receptor NR1H4
Nuclear receptor subfamily 1 group I member 2 NR1I2
G-protein coupled bile acid receptor 1 GPBAR1
Aldo-keto reductase family 1 member C2 AKR1C2

Referensi & Sumber

Synthesis reference: Henry Francis Frost, Fritz Fabian, Christopher James Sharpe, William Arthur Jones, "Process for preparing chenodeoxycholic acid." U.S. Patent US4022806, issued October, 1974.

Contoh Produk & Brand

Produk: 5 • International brands: 1
Produk
  • Chenodal
    Tablet, film coated • 250 mg/1 • Oral • US • Generic • Approved
  • Chenodal
    Tablet, film coated • 250 mg/1 • Oral • US • Generic • Approved
  • Chenodeoxycholic Acid Leadiant
    Capsule • 250 mg • Oral • EU • Approved
  • Chenodiol
    Tablet, film coated • 250 mg/1 • Oral • US • Generic • Approved
  • Chenodiol
    Tablet, film coated • 250 mg/1 • Oral • US • Generic • Approved
International Brands
  • Chenix — Sigma Tau

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul